Alembic Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• Alembic Pharmaceuticals Ltd reported a 11.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.2%.
• Its expenses for the quarter were up by 11.0% QoQ and 13.1% YoY.
• The net profit increased 19.6% QoQ and increased 20.0% YoY.
• The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 9.4 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alembic Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. The company offers a broad range of branded and generic formulations, as well as active pharmaceutical ingredients (APIs). Alembic's operations span across various therapeutic segments including antibiotics, anti-infectives, analgesics, and more. The company is well-regarded for its focus on innovation and research, continually expanding its product portfolio to meet market demands. Any recent major developments specific to the company are not available within the provided data.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Alembic Pharmaceuticals Ltd reported a total income of ₹1917.06 crores. This represents an increase of 11.6% from the previous quarter (Q1FY26), where total income stood at ₹1717.22 crores. Year-over-year (YoY), there was a notable rise of 15.2% from the same quarter last year (Q2FY25), when total income was ₹1664.72 crores. These figures suggest a strong growth trajectory in the company's revenue stream over both the quarterly and yearly periods observed.

Profitability

Alembic Pharmaceuticals Ltd's profitability metrics for Q2FY26 reveal a profit before tax of ₹222.30 crores, which marks a quarter-over-quarter (QoQ) growth of 16.7% from ₹190.56 crores in Q1FY26. Compared to Q2FY25, this is a year-over-year (YoY) increase of 23.8% from ₹179.56 crores. After accounting for taxes, the profit after tax for Q2FY26 was ₹183.71 crores, up 19.6% from the previous quarter and 20.0% from the same quarter last year. The earnings per share (EPS) in Q2FY26 was ₹9.40, reflecting a QoQ rise of 19.7% from ₹7.85 in Q1FY26 and a YoY increase of 20.7% from ₹7.79 in Q2FY25. These figures indicate substantial improvements in the company's profitability over the periods analyzed.

Operating Metrics

During Q2FY26, Alembic Pharmaceuticals Ltd incurred total expenses amounting to ₹1694.76 crores, which represents an 11.0% rise from ₹1526.66 crores in Q1FY26. Year-over-year, total expenses increased by 13.1% from ₹1498.03 crores in Q2FY25. The tax expense for the quarter stood at ₹40.01 crores, showing a 9.7% increase QoQ from ₹36.48 crores in Q1FY26 and a significant 46.7% YoY rise from ₹27.28 crores in Q2FY25. These operating metrics provide insight into the company's cost dynamics and tax obligations over the specified periods.